Introduction {#sec1}
============

With an estimated 171 million carriers, hepatitis C represents a public health burden globally.^[@ref1]^ Hepatitis C virus (HCV) infection is a major cause of chronic liver diseases including hepatocellular carcinoma (HCC). HCV is categorized in the Hepacivirus genus of the Flaviviridae family. Its genome is a 9.6 kb long positive strand RNA encoding a single polyprotein of about 3010 amino acids.^[@ref2]^ The cleavage of this polyprotein by cellular and viral proteases gives rise to 10 smaller proteins including three structural proteins (core, E1, and E2) and seven nonstructural proteins (P7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).^[@ref3]^ The nonstructural proteins have critical functions in viral replication.^[@ref4]^ Of these, NS3/4A assumes incredible significance as it is involved in many functions including suppression of the antiviral mechanism by evading host immune strategies. The NS3/4A protease has been shown to interfere with the pathogen recognition TLR3- and RIG-I/MDA5-mediated signaling pathways, by cleaving TRIF and MAVS signaling adaptors, respectively. This prevents the activation of type-I interferon stimulated genes (ISGs). For these reasons, the NS3/4A protease represents one of the most attractive targets for anti-HCV drug discovery.^[@ref5]−[@ref7]^

NS3 protease is a Zn(II)-dependent, chymotrypsin-like serine protease in which the catalytic triad (Ser139, His57, and Asp81) performs the enzymatic reaction.^[@ref8],[@ref9]^ A majority of the current direct acting antivirals (DAAs) inhibit the catalytic activity of NS3 protease. However, a high replication rate and low fidelity of HCV RNA-dependent RNA-polymerase (RdRp) leads to the generation of heterogenous viral population and quasi-states leading to accumulation of drug-resistant mutations in NS3 protease and rendering the drugs less-effective.^[@ref10]−[@ref13]^ As a result, the search for classes of lead compounds assumes significance. In these efforts, we and others have reported successful attempts for the use various plant extracts and their derivatives to regulate the HCV infection.^[@ref14]−[@ref16]^ For example, punicalagin from pomegranate,^[@ref16]^ curcumin from turmeric,^[@ref17]^ silymarin from milk thistle^[@ref18]^ exhibit considerable anti-HCV activity. In an earlier work, we demonstrated that the extract of the age-old folk plant, *Phyllanthus amarus*, successfully inhibited NS3 and NS5B-RdRp enzymes.^[@ref19]^ Recently, we have also shown that corilagin, one of the active ellagitannins of the *P. amarus* extract, could inhibit HCV NS3 protease activity at sub-micromolar concentrations and NS5B-RdRp activity at higher concentrations.^[@ref14]^

Phyllanthin is one of the active lignin, present in the leaf extracts of *P. amarus*. Earlier reports have demonstrated antioxidant, anticancer, antidiabetic, hepatoprotective and anti-inflammatory properties of phyllanthin.^[@ref20]−[@ref22]^ There are also reports which probed the role of phyllanthin in treating hepatitis B virus infection.^[@ref23]^ In the present study, we report that phyllanthin, in its natural form, is capable of inhibiting NS3 protease activity. As phyllanthin is less water-soluble and has poor bioavailability, a rational structure-based design approach is exercised to identify phyllanthin structural congeners. The 1,4-diphenyl butane scaffold of phyllanthin with C-2, C-3 substitutions provides an opportunity to derive the structural congeners. The substitution pattern at C-2 and C-3 carbons was planned. The Stobbe condensation reaction of succinic ester with aromatic aldehydes was planned in order to synthesize the structural congeners. Following the synthesis of congeners, the compounds are evaluated for their NS3/4A protease inhibitory activity *in vitro*. Among these compounds, a dicarboxylic acid derivative, annotated as **D8**, has been observed to inhibit the NS3 protease inhibitory activity more effectively than phyllanthin. The aqueous solubility of **D8** is the key reason for its better NS3 protease inhibition and bioavailability *in vivo* compared with parental phyllanthin. The systematic docking study enables evaluation of the mode of **D8** binding to the active site of the protease. Furthermore, *in vivo* studies of **D8** derivative proves its nontoxicity, bioavailability, and hence, safer use. Results of the computational, chemical and biological studies leading to identification of **D8** as a potent HCV NS3 protease inhibitor are presented herein.

Results {#sec2}
=======

One of the most promising approaches to an effective antiviral therapy is the development of small molecule inhibitors directed against the viral NS3 serine protease, which is an essential component required for the maturation of HCV polyprotein.^[@ref24]^ Phyllanthin (Phy) is constituted with 1,4-diphenyl butane scaffold, with methoxymethyl and methoxy substituents in the butane and phenyl segments, respectively. Aqueous solubility of as isolated phyllanthin is 0.25 mg mL^--1^, necessitating further studies to be conducted in a mixture of organic-aqueous mixtures. The substituents around the scaffold provide an opportunity for modifications.

The importance of phyllanthin scaffold in binding to NS3 protease was assessed initially through a docking analysis. Similarities were observed between the aromatic rings and methoxy functional groups of matairesinol and phyllanthin structures. Matairesinol is a ligand bound to a dehydrogenase (PDB id: 2BGM),^[@ref25]^ whose catalytic triad (Ser, Tyr and Lys) is similar to the catalytic triad residues of NS3 protease (Ser, Asp, and His). Our earlier studies have also demonstrated that the serine proteases, in general, are inhibited in the catalytic region. We have shown that at least 16 interactions could be correctly predicted in the docked NS3-telaprevir model with the aid of Autodock 4.2.^[@ref16]^ Hence, to predict the binding mode of phyllanthin, it was docked into the active site of NS3 protease using Autodock 4.2. The interactions predicted by docking are shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}, where hydrogen bonds between two of the three catalytic residues (Ser139 and His57) of NS3 protease and phyllanthin are shown. Other contacts between phyllanthin and NS3 are formed by Ala156, Lys136, and Val132. The interaction energy for this binding is calculated to be −3 kcal mol^--1^. Keeping in view that computational analysis showed the importance of hydrogen bonding and aromatic stacking interactions at the catalytic triad of phyllanthin--NS3 protease complex, the modifications warranted retaining the structural features intact for the above interactions.

![Molecular docking of the phyllanthin molecule with HCV NS3 protease. Color code: wheat: HCV NS3-protease; orange: phyllanthin; cyan: residues of the binding pocket which are involved in interactions. Zoom: view of the important interactions. Cyan: NS3 protease; pink: hydrogen bond interactions; black: hydrophobic interactions.](ao0c00786_0001){#fig1}

Chemical Synthesis {#sec2.1}
------------------

The chemical synthesis of phyllanthin structural congeners allowed variabilities in synthons undergoing the assembly to target molecules. [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} shows the congener structures that are designed and synthesized in the present study.

![Molecular structures of phyllanthin (Phy) and congeners **1--3**.](ao0c00786_0002){#fig2}

Naturally occurring phyllanthin (Phy) was extracted from *P. amarus* as reported previously.^[@ref26]^ One of the early modifications planned was at C-2, C-3 carbons at the methoxymethylene side chain functionalities. A Stobbe condensation reaction of 3,4-dimethoxy benzaldehyde with diethyl succinate under basic condition formed the route to synthesize the congeners **1--3** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis of Congeners **1--3**](ao0c00786_0010){#sch1}

3,4-Dimethoxy benzaldehyde was reacted with diethyl succinate, under a basic condition. Following work up, the reaction mixture was subjected to methyl ester formation upon treatment with SOCl~2~/MeOH. Purification of the reaction mixture afforded mono- and bis-substitution products.^[@ref27]^ The desired monosubstitution product was isolated and subjected to Pd--C-mediated reduction to secure **1**, in a moderate yield. In subsequent reactions, a base-mediated hydrolysis of ester functionalities afforded derivative **2**,^[@ref28]−[@ref30]^ whereas an LAH-mediated reduction afforded bishydroxymethyl derivative **3**. Both these derivatives were obtained in good to excellent yields. Physical characterizations are performed by NMR spectroscopy, mass spectrometry ascertained the structural homogeneities of derivatives **1--3** (**D7--D9**), and these derivatives are racemic.

Biochemical and Biological Evaluations {#sec2.2}
--------------------------------------

### Effect of Phyllanthin and Its Synthetic Derivatives on HCV NS3/4A Protease Activity *In Vitro* {#sec2.2.1}

Phyllanthin (Phy) and three synthetic derivatives (Phy, **D7--D9**) were tested at first, in a fluorometric reaction-based NS3/4A protease activity assay. Among the synthetic derivatives tested in this assay, **D8** was found to be the most effective inhibitor with an IC~90~ of 50 μM ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}), and thus, subsequent studies were focused on this derivative.

![Effect of phyllanthin (Phy) and its derivatives (50 μM) on HCV NS3/4A protease activity. Inhibitions were compared with a standard control reaction with no test compound (Std) as 100%. Symbol \* indicates a statistical significance with the *P* value (\<0.05).](ao0c00786_0003){#fig3}

In order to investigate whether the inhibitory effect is dose-dependent, the above assay was performed at varying **D8** concentrations, in the range from 10 to 100 μM. A dose-dependent NS3 protease inhibition activity was observed, and complete inhibition occurred at 75 μM of **D8**. Telaprevir, a standard NS3 protease inhibitor, was used as the positive control in this assay ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a).

![(a) Concentration-dependent inhibitory effect of **D8** on NS3/4A protease activity used as a standard control. (b) Effect of **D8** on cellular serine protease activity. Trypsin was incubated with the substrate in the presence of increasing concentrations of **D8**. Inhibitions were compared with a standard control reaction with no test compound (Std) as 100%. In this assay, the *G. max* soyabean inhibitor^[@ref14]^ was used as a positive control. Symbol \* indicates a statistically significant difference in terms of the *P* value (\<0.05).](ao0c00786_0004){#fig4}

### Structural Basis of NS3 Protease Inhibition by **D8** {#sec2.2.2}

The experimental studies showed several fold higher efficacy for **D8** when compared to native phyllanthin. Hence, molecular docking was performed to further understand the interactions of **D8** with NS3 protease enzyme ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). **D8** showed better interaction profile than phyllanthin as observed by binding energy of −5.7 kcal mol^--1^ for **D8** vis-à-vis the binding energy of −3 kcal mol^--1^ for phyllanthin. While **D8** was also found to make interactions with Ser139 and His57 of the NS3 protease catalytic triad, it was observed that the presence of two carboxylic acid moieties further help **D8** in making charged interactions with NH~3~^+^ of Lys136 from NS3 protease. These charged interactions contribute favorably to the binding energy. Phyllanthin, which lacks charged substituents, was unable to make these interactions and instead was found to be involved in the hydrogen bond with Lys136 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Furthermore, despite the presence of the aromatic ring in both phyllanthin and **D8**, it is in the **D8**/NS3 docked complex that the aromatic ring is properly stacked with His57 and contributes toward the aromatic stacking interactions ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). In the phyllanthin--NS3 docked complex, the aromatic ring is unable to stack properly with His57. Also, Ala156, which is one of the substrate-binding residues, participates in the hydrophobic interaction with **D8**. It is likely that D8 being smaller in size orients better with the catalytic residues as compared to phyllanthin, the fitting of which might be restricted because of the presence of other substituents. All these interactions contribute favorably to the interaction energy between **D8** and NS3-protease, which can be considered as an indicator for stronger binding as compared to native phyllanthin. Taken together, although **D8** is nearly half of the phyllanthin molecular structure, it can make better interactions with NS3 protease catalytic residues and thus better efficacy in the inhibition activities.

![Molecular docking of **D8** with HCV NS3 protease. (a) Left side shows the minimum energy binding of the **D8** molecule to HCV NS3-protease (pale cyan) as obtained after docking. The **D8** molecule is depicted in salmon color, and the residues of the binding pocket which are involved in interactions with it are shown in green. The right side shows the zoomed-in view of the important interactions. The NS3 protease residues are labeled and shown as sticks (green), and the interactions are shown as dotted lines. The pink color depicts hydrogen bond interactions, red depicts charged interactions, and black color depicts hydrophobic interactions. (b) Superposition of phyllanthin (orange) and **D8** (salmon) in the binding pocket of NS3 protease (in gray). The catalytic residues are shown in cyan. The orientation of NS3 protease is different in A and B for representation purpose.](ao0c00786_0005){#fig5}

### **D8** is Specific to HCV NS3 Protease {#sec2.2.3}

The specificity of the **D8** inhibition effect against HCV NS3 protease was conducted using another serine protease (cellular), namely, trypsin in a fluorometric assay. This assay involves cleavage of a casein substrate labeled with fluorescein isothiocyanate (FITC) by trypsin.^[@ref31]^ The intensity of the fluorescence signal evolving from the cleaved FITC substrate in the presence of **D8** is a quantitative measure of its inhibitory effect. Increasing concentrations of **D8** were used in this assay. However, **D8** did not show an inhibition, even at 250 μM. In contrast, an already known trypsin inhibitor from *Glycine max* soyabean,^[@ref14]^ used here as a positive control, drastically reduced the trypsin activity. The assay suggested that **D8** is a specific inhibitor of HCV NS3 serine protease ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b).

### **D8** is Considerably Nontoxic to Huh7.5 Cells Compared to Native Phyllanthin {#sec2.2.4}

As HCV replication in cell culture is limited to Huh7/Huh7.5 cells, toxic effect, if any, of **D8** against these cells was assessed. The treatment of **D8** up to 5 mM to Huh7.5 cells did not induce any toxicity (CC~50~ \> 5 mM) in MTT assay, whereas more than 50% cell death was observed upon the treatment of phyllanthin at 5 mM. CC~50~ \> 5 mM suggests **D8** is significantly tolerable, as compared to native phyllanthin ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"} and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

![MTT assay to compare the effect of **D8** and phyllanthin (Phy) on cell viability. "C" represents control, namely, untreated Huh7.5 cells. Data represent mean ± SD from three independent experiments. Statistical significance is shown as \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](ao0c00786_0006){#fig6}

###### Effect of Phyllanthin and **D8** on HCV RNA Replication *Ex Vivo* in Rep2a and Cell Viability *Ex Vivo*[a](#t1fn1){ref-type="table-fn"}

                HCV RNA replication in Rep2a cell line   cell viability (MTT assay)
  ------------- ---------------------------------------- ----------------------------
  phyllanthin   250                                      5.0
  **D8**        75                                       \>5.0

Note: EC~50~ = 50% of effective concentration; CC~50~: 50% of cellular cytotoxicity.

### **D8** Significantly Inhibits HCV Replication in Cell Culture {#sec2.2.5}

Following the successful assessment of toxicity of **D8**, the effect of **D8** on HCV replication in the cell culture was performed. For this, Huh7 cells harboring HCV monocistronic replicon ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}a) were incubated with increasing concentrations of **D8**. At 48 h post-treatment, HCV negative strand synthesis was quantified using RT-qPCR. Cells treated with **D8** showed significant decrease in HCV RNA levels in a concentration-dependent manner. Also, this decrease was relatively more for **D8**, as compared to cells treated with phyllanthin ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}b and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), demonstrating better potency of **D8** in inhibiting HCV replication.

![(a) Schematic representation of HCV monocistronic replicon; (b) HCV negative strand synthesis measured by RT-qPCR. "C" represents no treatment. Telaprevir was used as a standard positive control.](ao0c00786_0007){#fig7}

### **D8** Showed Higher Tolerance in BALB/C Mice Compared to Native Phyllanthin {#sec2.2.6}

In order to assess the safety of **D8***in vivo*, acute and subacute toxicity analyses were performed. In acute toxicity study, BALB/c mice were orally fed with increasing doses (0--5000 mg/kg b. wt) of **D8** and phyllanthin. The maximum acute tolerance dose of **D8** was observed to be 4000 mg/kg/b. wt. At 5000 mg/kg b. wt, 40% death of mice was observed. However 100% death of mice was observed at 5250 mg/kg b. wt (50% lethal dose (LD~50~) of **D8** lies between 5000 and 5250 mg/kg b. wt). The tolerance dose of **D8** was ∼2.5 times higher than that of phyllanthin (1500 mg/kg/wt) and 100% death of mice observed at 2000 mg/kg b. wt. Suggesting that, the LD~50~ for phyllanthin was found to be between 1500 and 2000 mg/kg b. wt ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}a--d). The body weights of mice from control groups, as well as acute tolerance doses of **D8** via other modes of administrations (intravenous and intraperitoneal) in mice were also determined (data shown in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00786/suppl_file/ao0c00786_si_001.pdf)).

![Oral toxicity effect of phyllanthin and **D8** in BALB/c mice. In acute toxicity studies, panels (a,b) show the maximum tolerance, whereas (c,d) show the induction of mortality at lethal doses of compounds. Sub-acute toxicity studies, figures (e,f) show no observed adverse effect of compounds after repeated administration (∼1/4th of the maximum tolerance dose) of compounds for 28 consecutive days. Note that sudden dropping lines to the x axis in figures c,d indicate death of the mice.](ao0c00786_0008){#fig8}

On the other hand, subacute toxicity study involved repeated administrations of **D8** (1000 mg/kg b. wt/day/mouse), water (200 μL/day/mouse), PEG-400 (200 μL/day/mouse), and phyllanthin (500 mg/kg b. wt/day/mouse) for 28 consecutive days. All the treated mice groups did not exhibit any undesirable changes in general behavior and body weights compared to control groups ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}e,f).

### Treatment with **D8** Does Not Alter the Histoarchitecture of the Mice Liver {#sec2.2.7}

As external signs of toxicity of **D8** were not observed, histopathological analyses were performed next, so as to ensure no internal damage at the tissue level. Histology of the mice liver treated with **D8** at maximum acute tolerance dose (4000 mg/kg b. wt p.o) showed normal histoarchitecture compared to the vehicle control (water). Similar observations were obtained for phyllanthin (1500 mg/kg b. wt p.o) and its vehicle control (PEG-400) groups \[[Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}a(i--iv)\].

![(a) Histopathological examination of the mice liver. A representative picture from the different groups (1--4) in the acute toxicity studies, (i) water control; (ii) **D8** 4000 mg/kg b. wt; (iii) PEG-400 (300 μL/mouse); (iv) phyllanthin (1500 mg/kg b. wt.). Similarly, the groups (5--8) in the subacute toxicity study, (v) water control; (vi) **D8** (1000 mg/kg b. wt/day); (vii) PEG-400 (200 μL/day/mouse); (viii) phyllanthin (500 mg/kg b. wt/day). Arrow indicates multifocal aggregation of hematopoietic cells and liver necrosis. (b) Bioavailability of **D8** (500 mg/kg b. wt p.o) and phyllanthin (1500 mg/kg b. wt p.o) in BALB/c mice. Values used to plot AUC are mean ± SD from the three independent experiments.](ao0c00786_0009){#fig9}

The liver sections of mice orally administrated with subacute dose of **D8** (1000 mg/kg b. wt/day) for 28 days also showed normal histology. However, the histoarchitecture of mice livers obtained 28 days after repeated feeding of phyllanthin (500 mg/kg b. wt/day) showed tissue necrosis and multifocal aggregation of hematopoietic cells along with necrotic foci at some parts. It appears that the induction of liver necrosis could be due to repeated dosage of PEG-400, as similar features were observed in the mice group treated with PEG-400 alone \[[Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}a(v--vii)\]. Taken together, these observations suggest that the aqueous solubility feature confers an advantage to **D8** for its completely nontoxic behavior over its water-insoluble parental counterpart, namely, phyllanthin.

### Orally Administered **D8** is Systemically Bioavailable {#sec2.2.8}

It is important for a compound to be first absorbed into the blood in the process to reach a target tissue and exert its effects. As orally administered **D8** did not show any toxic effect, it is pertinent to verify whether **D8** is systemically available in blood and rule out the possibility of its unabsorbed elimination. Accordingly, mice were orally fed with 500 mg/kg b. wt of **D8**, and HPLC analyses were performed on plasma samples collected at different time points. Phyllanthin was also included in these assays for comparison. Results showed good systemic absorption of **D8** with maximum bioavailability at 1 h (*T*~max~: 1 h). The half-life time (*t*~1/2~) of the compound and maximum concentration (*C*~max~) were observed as 2 h and ∼595 μg mL^--1^, respectively. In contrast, we could not observe any bioavailability (up to 24 h) in the mice group fed with phyllanthin at the same dose of 500 mg/kg b. wt p.o. A very low concentration of absorbed phyllanthin could only be observed when administered at a higher dose (1500 mg/kg b. wt) ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}b). These observations proved better bioavailability of **D8** over phyllanthin which might be due to its smaller size and increased aqueous solubility.

Discussion {#sec3}
==========

The present study shows a structure-guided approach to identify potent derivatives inhibiting the activity of a serine-protease, namely, NS3/4A protease, a nonstructural protease having a critical role in the HCV viral replication. NS3/NS4A is a noncovalent, heterodimer complex formed by two HCV-encoded proteins, the N-terminal serine protease domain of NS3 (catalytic subunit) and the NS4A cofactor (activation subunit). This protein complex performs multiple important functions in HCV-infected cells, for example, NS3/4A is responsible for the proteolytic cleavages at the junctions of nonstructural proteins downstream of NS3 (NS3/NS4A, NS4A/NS4B, NS4B- NS5B-, and NS5A-NS5B) of the HCV polyprotein.^[@ref32],[@ref33]^ Apart from this, it also directs proteolysis of its proline-rich adaptor protein, toll-IL-1 receptor domain-containing adaptor-inducing interferon-β (TRIF) and MAVS in the mitochondria, thus helps virus evade innate immunity by dislodging a pivotal antiviral protein from the mitochondria.^[@ref34],[@ref35]^ Interestingly, the TRIF cleavage site has been described to have remarkable homology with the viral NS4B/5A substrate.^[@ref34]^ Emphasis on this protease also arises as mutations in NS3 protease leads to multidrug resistance of the virus, abolishing its susceptibility to drugs, including direct acting antivirals.^[@ref36],[@ref37]^ Our earlier study demonstrated that phyllanthin, a major constituent of the *P. amarus* extract, possesses a significant antiviral activity. NS3 protease was found to be the target enzyme to the phyllanthin inhibition activity. The aqueous solubility of phyllanthin was a major constraint, warranting a structure-based approach to identify most potent structures from a pool of structural congeners. A computational docking study of phyllanthin with the NS3 protease enzyme catalytic region revealed key ligand--receptor interactions, primarily that of aromatic stacking and hydrogen bonding interactions. Thus, structural modifications of the phyllanthin scaffold required retaining the moieties that promote these interactions.

Phyllanthin is a 1,4-diphenyl butane derivative possessing methyloxymethylene substituents at C-2 and C-3 carbons. Synthesis of congeners of this scaffold could be planned when the scaffold is also considered as benzylic substitutions at C-2 and C-3 carbons on a succinoyl synthon. Stobbe condensation of succinic acid esters with aromatic aldehydes as electrophilic acceptors is a suitable approach to synthesize congeners of phyllanthin. In effect, Stobbe condensation is used beneficially to synthesize the congeners or derivatives that possess aromatic and side chain functionalities to promote interactions with the receptor catalytic sites. The chemical synthesis also permits the side-chain functionality modifications at the alkyl segment. Furthermore, the synthesis afforded structures constituted with only one benzylic moiety in the succinoyl segment at C-2, without the presence of another benzylic moiety at C-3.

Having the congeners with varied functionality modifications, the efficacies of congeners to inhibit the NS3 protease activity was evaluated initially. Using the fluorometric assay, the emergence of fluorescence from the cleavage of the green fluorescent protein, namely, EGFP-NS5A/B-CBD, was utilized to identify the inhibitory potencies of the NS3 protease activity by synthetic congeners. Of the compounds studied in this assay, a derivative annotated as **D8** was found to be the efficient inhibitor, surpassing the inhibition potency of native phyllanthin. Computational docking assessment of the interaction of **D8** with NS3 protease indeed revealed a stronger binding energy in favor of **D8**, in comparison to native phyllanthin. This increased energy results from additional interactions between carboxylic acid moiety of **D8** and proximal Lys residues at the catalytic triad of NS3 protease, a feature which is absent in the binding of phyllanthin with the same receptor. A series of subsequent experiments were undertaken with the **D8** derivative, in efforts to establish the inhibition profile of this derivative.

A comparison to another protease, namely, trypsin, shows that inhibition of trypsin activity by **D8** does not occur even at 250 μM, whereas the known trypsin inhibitor from *G. max* soyabean showed inhibition concentration IC~50~ at 1 μM. Thus, **D8** retains a specificity as an inhibitor of NS3 protease, with IC~50~ \< 10 μM, whereas native phyllanthin required an IC~50~ concentration of ∼50 μM.

The efficacy of **D8** as the NS3 protease inhibitor warranted the assessment of the toxicity. When conducted in a thiazolium-based MTT assay on the Huh7.5 cell line, no perceptible cellular toxicity was observed with **D8**, even at 5 mM concentration, and phyllanthin exhibited 50% cell death at this concentration. When the same cell line harbored with HCV monocistronic replicon was treated with **D8**, a significant reduction in the HCV RNA replication is observed. The reduction in RNA replication is concentration-dependent and at 250 μM, the reduction in HCV negative strand synthesis was matching that of the inhibition by Telapravir. These *in vitro* assays established the inhibitory efficacy of **D8**, in comparison to native phyllanthin. Furthermore, augmented by higher aqueous solubility, assessments were taken up, so as to adjudge the validity of **D8** as the potent inhibitor under the *in vivo* conditions. The *in vivo* toxicity experiments on Balb/c mice revealed a maximum acute tolerance of **D8** on the mice at a concentration of 4000 mg/kg body weight of the mice. Repeated dosing **D8** at 1000 mg/kg body mass also revealed significantly enhanced sub-acute toxicity of **D8**, in comparison to phyllanthin. These studies reveal that **D8** possesses a significantly enhanced inhibition potency, outweighing the same exhibited by phyllanthin. Histopathological profiles of mice treated with **D8**, phyllanthin, and carrier control PEG400 also enabled to establish the complete preservation of histoarchitecture of liver sections on mice treated with **D8** at the maximum acute tolerance concentration of 4000 mg/kg body mass, an effect which was not observed with phyllanthin and the carrier control, each of which exhibited loss in the histoarchitecture at much lesser concentrations.

Bioavailability of the inhibitors in mice blood circulation, when assessed through the HPLC technique on plasma samples withdrawn at varying time points, demonstrated a good bioavailability of **D8** after 1 h, when orally fed with 500 mg/kg of body mass. After 2 h, plasma samples contained 595 μg mL^--1^. These results show a good systemic circulation of **D8**, and such a bioavailability was absent with native phyllanthin at such a concentration. The bioavailability of **D8** may thus not be a limiting factor in advancing this new chemical entity.

The number of studies conducted on **D8** as described above establishes that **D8** is a newly discovered inhibitor of NS3 protease, which is one of the nonstructural proteins that regulate HCV replication and disease progression. A structure-based design effort, initiated from the phyllanthin core structure, has enabled us to discover this new inhibitor **D8**, presenting a formidable scope to develop further advanced studies toward a potent practical application of **D8** to contain HCV infection.

Conclusions {#sec4}
===========

The present study demonstrates a structure-based approach in order to identify structural congeners of phyllanthin as novel, potent inhibitor NS3 protease, a nonstructural protein involved with the HCV viral replication and disease progression. Facile synthesis by Stobbe condensation allowed construction of the congeners, initiated by the reaction of succinic ester with vanillin. The reaction led to mono- and disubstitution at the C-2 and C-3 carbons of succinic ester. The monosubstitution product of Stobbe condensation was taken through further modifications by either ester hydrolysis or ester reduction. Among three congeners, namely, a diester (**D7**), dicarboxylic acid (**D8**), and diol (**D9**), **D8** exhibits a profound inhibition of the NS3/4A protease activity, at 75 μM concentration, for complete inhibition. A molecular docking study revealed that charged interactions were accrued further between carboxylic acid moieties of **D8** and NH~3~^+^ side chain functionality of Lys136 residue located at the catalytic triad site of NS3 protease. Further studies leading to the assessment of the noncytotoxicity profile, inhibition of HCV replication, *in vivo* tolerance, and unalteration of the histoarchitecture of treated mice demonstrate that **D8** surpasses phyllanthin in its inhibitory potency. The bioavailability of **D8** further adds to the "drug-like" activity profile. The present study establishes that **D8** is a new chemical entity, providing a greater scope to counter HCV viral infection.

Materials and Methods {#sec5}
=====================

General Methods {#sec5.1}
---------------

All reactions were carried out under a nitrogen atmosphere. Organic extracts were dried over anhydrous sodium sulphate. Solvents were removed in a rotary evaporator under reduced pressure. Silica gel (100--200 mesh size) was used for the column chromatography. Reactions were monitored using silica gel 60 F254-coated TLC plates. ^1^H NMR spectra were measured on an NMR instrument, operating at 400 MHz for ^1^H nucleus and 100 MHz for ^13^C nucleus, and the chemical shifts were calibrated with respect to tetramethylsilane or residual solvent peaks, as the internal standard. High-resolution mass spectra were recorded on an electrospray-QTOF instrument.

### Plasmid Constructs and Reagents {#sec5.1.1}

Plasmids pYB-43 (single-chain HCV NS3/4A) and pYB-44 (EGFP-NS5A/B-CBD) encoding protease domain of NS3 and fusion substrate protein,^[@ref36]^ respectively, were received as a kind gift from Dr. Itai Benhar, Tel Aviv University, Israel.

### Cell Lines {#sec5.1.2}

The Huh7.5 cell line was received from Dr. C. M. Rice, Rockefeller University, USA. Huh7 cells harboring HCV monocistronic replicon genotype 2a (Rep2a)^[@ref37]^ was received as a kind gift from Dr. Ralf Bartenschlager, Heidelberg University. All cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 U/mL of penicillin (HiMedia), and 100 μg/mL of streptomycin sulphate (HiMedia). For Rep2a cell line maintenance, 25 μg per mL of Hygromycin B (Himedia) was added to the culture medium. All cell lines were maintained at 37 °C in 5% CO~2~.

### Dimethyl 2-(3,4-dimethoxybenzyl)succinate (**1**) (**D7**) {#sec5.1.3}

NaH (0.9 g, 36 mmol) was added to a stirred solution of 3,4-dimethoxy benzaldehyde (3.0 g, 9.06 mmol) and diethyl succinate (3.18 g, 18.0 mmol) in PhMe (60 mL) at 0 °C. The reaction mixture was refluxed for 12 h, cooled, quenched with aq. HCl (5% v/v), extracted with ethyl acetate (4 × 20 mL), washed with water (3 × 10 mL), the organic layer was dried, solvents were evaporated *in vacuo*, and the residue was dried under high vacuum to afford the crude product (3.42 g, 72%). The residue (3.2 g, 12.0 mmol) in MeOH (60 mL) was treated with SOCl~2~ (2.60 mL, 30.0 mmol), the mixture was stirred at 0 °C for 6 h and at room temperature for 6 h. Solvents were evaporated *in vacuo*, the resulting product was dried under high vacuum and purified by column chromatography (SiO~2~) (pet. ether/EtOAc linear gradient) to afford a crude product as an amorphous powder (2.97 g, 84%). A suspension of this intermediate (2.7 g, 4.5 mmol) in MeOH (50 mL) and Pd--C (10%) (2.5 g) was stirred under a H~2~(g) atmosphere for 12 h, filtered through celite, washed with MeOH (30 mL), solvents evaporated *in vacuo*, and the resulting crude product purified by column chromatography (SiO~2~) (pet. ether/EtOAc linear gradient) to afford **1** as a gummy solid (1.56 g, 80%). ^1^H NMR (CDCl~3~): δ 6.70 (s, 1H, Ar), 6.60 (app. s, 2H, Ar), 3.75 (s, 3H, OMe), 3.73 (s, 3H, OMe), 3.56 (s, 3H, CO~2~Me), 3.53 (s, 3H, CO~2~Me), 3.01 (m, 1H, CH~2~), 2.90 (m, 1H, CH), 2.60 (m, 2H, CH~2~), 2.31 (app. dd, *J* = 12, 4 Hz, 1H, CH~2~); ^13^C NMR (CDCl~3~): δ 174.3 (C=O), 171.9 (C=O), 148.5 (Ar), 147.4 (Ar), 130.2 (Ar), 120.7 (Ar), 111.6 (Ar), 110.8 (Ar), 55.3 (OMe), 51.4 (CO~2~Me), 51.3 (CO~2~Me), 42.7 (CH), 36.9 (CH~2~), 34.4 (CH~2~). ESI-MS *m*/*z* \[M + Na\]^+^; calcd for C~15~H~20~O~6~Na, 319.1158; found, 319.1156.

### 2-(3,4-Dimethoxybenzyl)succinic Acid (**2**) (**D8**) {#sec5.1.4}

A mixture of **D7** (1.4 g, 4.5 mmol) and LiOH.H~2~O (1.90 g, 45 mmol) in THF/water (5:1) (60 mL) was refluxed for 12 h, neutralized with Amberlite resin (H^+^ form), filtered, washed with Et~2~O (25 mL), the filtrate was dried, and solvents were evaporated *in vacuo* to afford **2** as an oil (1.18 g, 98%). ^1^H (CDCl~3~): δ 10.05 (br. S, 2H, OH), 6.78 (d, *J* = 8.0 Hz, 1H, Ar), 6.69 (d, *J* 8.0 Hz, 2H, Ar), 3.82 (s, 6H, OMe) 3.00 (m, 2H, CH~2~), 2.73 (m, 2H, CH~2~), 2.45 (m, 1H, CH); ^13^C (CDCl~3~): δ 180.3 (CO~2~H), 178.0 (CO~2~H), 149.0 (Ar), 147.9 (Ar), 130.1 (Ar), 121.2 (Ar), 112.0 (Ar), 111.3 (Ar), 55.88 (OMe), 55.84 (OMe), 42.9 (CH), 36.9 (CH~2~), 34.4 (CH~2~). ESI-MS *m*/*z* \[M + Na\]^+^; calcd for C~13~H~16~O~6~Na, 291.0845; found, 291.0847.

### 2-(3,4-Dimethoxybenzyl)butane-1,4-diol (**3**) (**D9**) {#sec5.1.5}

Derivative **D7** (0.77 g, 1.29 mmol) in THF (20 mL) was added with LAH (0.14 g, 3.87 mmol), the reaction mixture was stirred for 12 h at room temperature, quenched with ice, solvents were evaporated *in vacuo*, dissolved in EtOAc (40 mL), washed with water (2 × 10 mL), dried, and evaporated *in vacuo* and purified by column chromatography (SiO~2~) (pet. ether/EtOAc linear gradient) to afford **3** as an amorphous solid (0.43 g, 80%). ^1^H NMR (CDCl3, 400 MHz): δ 6.70 (s, 1H, Ar), 6.62 (app. s, 2H, Ar), 3.90 (br, 2H, OH), 3.67 (s, 2H, OMe), 3.60--3.45 (m, 4H, OMe), 3.35--3.27 (m, 2H, CH~2~OH), 2.49 (m, 2H, CH~2~OH), 1.65 (m, 1H, CH), 1.50 (m, 4H, CH~2~); ^13^C NMR (CDCl~3~, 100 MHz): δ 148.6 (Ar), 147.1 (Ar), 132.8 (Ar), 121.0 (Ar), 112.2 (Ar), 111.0 (Ar), 65.2 (CH~2~OH), 60.7 (CH~2~OH), 55.7 (OMe), 41.1 (CH), 37.6 (CH~2~), 35.1 (CH~2~). ESI-MS *m*/*z* \[M + Na\]^+^; calcd for C~13~H~20~O~4~Na, 263.1259; found, 263.1277.

### HCV NS3 Protease Assay {#sec5.1.6}

The effect of phyllanthin (Phy) and synthetic derivatives (**D7**--**D9**) at 50 μM on HCV NS3/4A protease activity was assessed using a high throughput fluorimetric assay as described earlier.^[@ref38]^ Briefly, purified enzyme scNS3/4A (0.1 μM) was pre-incubated with a test compound (Phy, **D7**-**D9**), followed by the addition of purified fusion substrate protein (EGFP-NS5A/B-CBD, 0.5 μM). The reaction was incubated for another 1 h at 37 °C. The cleavage reaction was terminated by adding the cellulose slurry (40 μM) into the reaction mix. Then, reaction tube was centrifuged, and the supernatant was collected separately. Finally, the total amount of the fluorescence signal evolved from the cleaved EGFP substrate was quantified using a fluorimeter (Modulus TM Microplate Multimode Reader) using excitation filter 484 nm and emission filter 538 nm. Telaprevir (MedChem) was used as a positive control.

### Cellular Serine Protease Assay {#sec5.1.7}

In order to demonstrate the specificity of **D8**, only to HCV NS3 serine protease but not to the cellular serine protease, a simple high throughput *in vitro* cellular serine protease (trypsin) assay was performed using a protease fluorescent detection kit (PF0100, Sigma-Aldrich). In this assay, cellular trypsin was pre-incubated with increasing concentrations of the test sample followed by the addition of the casein substrate protein (conjugated with fluoresce in isothiocyanate, FITC) and further incubation for 1 h at 37 °C. The reaction was terminated by adding the trichloroacetic acid (6.1 N), and the supernatants were collected by centrifugation. The amount of fluorescence signals evolved from the cleaved substrate was quantitated by fluorometry using an excitation filter of 485 nm and an emission filter of 538 nm. The trypsin inhibitor from *G. max* (Sigma-Aldrich) was used as the positive control.

### Structural Analysis and Docking Protocol {#sec5.1.8}

Ligands similar to phyllanthin were searched by SMILES string (SMILES--the simplified molecular-input line-entry system: It describes the structure of chemical molecules) and molecular formula. Ligand bound protein structures were found using Ligand Expo and chemical component search in PDB.^[@ref38]^ Instead of blind docking, the knowledge derived from the crystal structure of the protein--ligand complex (PDB id: 2BGM) was used to selectively dock phyllanthin around the catalytic region of NS3 (PDB id: 1DY8) using Autodock 4.2.^[@ref39]−[@ref42]^ Following docking parameters were used:aPolar hydrogens were added wherever missing.bGasteiger charges were assigned.cPeptide bonds, amide bonds, guanidium bonds, and cyclic groups were treated as nonrotatable.dThe grid was defined on the catalytic pocket and the protein was considered to be rigid.eRuns (100 GA) with medium evaluation because the number of rotatable bonds \<10.

This directed docking was carried out upon observing the similarity between the functional groups of Matairesinol (PDB id: 2BGM) bound to similar catalytic triad residues of a dehydrogenase. The 3D structure of phyllanthin was obtained from PubChem.^[@ref41]^ The best ranked model with lowest binding energy was analyzed using PLIP server^[@ref42]^ and visualized using PyMOL (The PyMOL Molecular Graphics System Version 1.5.0.4).^[@ref43]^ Similar docking protocol was used to dock **D8** molecule with NS3 protease. Three-dimensional coordinates of **D8** was saved using ChemDraw.

### Cell Viability Assay {#sec5.1.9}

To investigate the cellular cytotoxicity, Huh7.5 cells were seeded in 96 well plates at a density of 2 × 10^4^ cells in 100 μL of DMEM media containing 10% serum and incubated overnight at 37 °C. After 12 h, cells were treated with different concentrations of phyllanthin, and its synthetic derivative, **D8**, was treated. Cytotoxic effects of phyllanthin verses **D8** on Huh7 cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma-Aldrich), as described earlier.^[@ref44]^

### HCV Replication Assay in Rep2a Cell Line {#sec5.1.10}

Huh-7 cells harboring the monocistronic replicon (7 × 10^4^) were seeded in a 12 well plates containing DMEM (Sigma-Aldrich) supplemented with 10% heat inactivated fetal bovine serum (FBS) (Gibco) at 37 °C.^[@ref37]^ In order to express the HCV subgenomic replicon system, 25 μg/mL of hygromycin B (Himedia) was used. After 12--16 h, the medium was changed, and the cells were treated with increasing concentrations of inhibitors (**D8**/phyllanthin) and further incubated to 48 h at 37 °C. Then, the total RNA was isolated using the TRIzol reagent, and HCV negative strand levels were quantified using analysis by reverse transcription quantitative PCR, as described earlier using HCV.^[@ref14]^

### Ethical Statement {#sec5.1.11}

Adult healthy BALB/c mice were obtained from the Institutional Centre Animal Facility. All study design was approved by the "Institutional Animal Ethics Committee". Animals were maintained in accordance with the guidelines of the Indian Law on animal care and use.

### Preparation of the Drugs for *In Vivo* Studies {#sec5.1.12}

The required concentrations of phyllanthin and **D8** were dissolved in polyethylene glycol-400 (PEG-400) and water respectively. These solvents alone were used as vehicle controls.

### Determination of Systemic Toxicity in Mice {#sec5.1.13}

For the safety assessment, the acute and sub-acute toxicity of phyllanthin and **D8** was determined according to OECD guidelines (423 and 407).^[@ref45],[@ref46]^ Hematoxylin and eosin stains were used to examine the histopathology of liver sections from treated and control groups of BALB/c mice. Body weight, food consumption, food and water intake, abnormal behavior, and adverse signs of toxicity were recorded throughout the study.

### Histopathological Analysis {#sec5.1.14}

The formalin fixed mice liver tissues from both the control and treated groups were routinely processed in different alcoholic gradients and embedded in paraffin wax. Microtome sections (5 μm thickness) were cut, and permanent slides were prepared using haematoxylin and eosin stains (Sigma-Aldrich). The slides were examined under a light microscope and analyzed for any pathological signs.

### Bioavailability of Phyllanthin and **D8** in Mice {#sec5.1.15}

A total of 50 BALB/c mice (divided into 2 groups of 25 mice each) were used for this assay. All the animals selected for the study were kept under fasting overnight and were orally administered with phyllanthin and **D8** separately to each group at 500 mg/kg b. wt/mouse. Blood was drawn by retro orbital puncture from three mice from each group at regular intervals between 0 and 24 h. Plasma was immediately separated by centrifuging blood for 2000 rpm for 20 min at 4 °C. Plasma thus obtained (500 μL) was mixed with the equal volume of 2% trifluoroacetic acid and subjected immediately to RP-HPLC using 0.02% acetonitrile and water as a mobile phase. The area under the curve (AUC) for plasma concentrations of phyllanthin and **D8** was plotted, and pharmacokinetics parameters including maximum plasma concentration (*C*~max~), time to reach concentration maxima (*T*~max~), and half-life time (*t*~1/2~) were calculated.

### Statistical Analyses {#sec5.1.16}

The results of all the experiments were expressed as the mean ± standard deviations (SD). The two-tailed unpaired "*t*" test was performed using GraphPad Prism 6.0 software to find out significance. The significant differences between the groups are represented by an asterisk (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001) compared with the control group (C).

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c00786](https://pubs.acs.org/doi/10.1021/acsomega.0c00786?goto=supporting-info).^1^H and ^13^C NMR spectra of **D7**--**D9** and *in vivo* toxicity of phyllanthin and **D8** administered *via* different modes in BALB/c mice ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00786/suppl_file/ao0c00786_si_001.pdf))
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